x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012345
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro109 of human NNMT protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NNMT |
| UniProt No. | P40261 |
| Gene ID | 4837 |
| Gene Description | Nicotinamide N-methyltransferase is a metabolic enzyme expressed primarily in liver and adipose tissue. It catalyzes the transfer of a methyl group from S-Adenosyl-methionine to nicotinamide, yielding 1-methylnicotinamide and S-Adenosyl-L-homocysteine. This N-methylation enzymatic activity plays an important role in the biotransformation of drugs and xenobiotics, and also contributes to the metabolism of vitamin B3. Knockdown of NNMT was shown to increase both SAM and NAD+ levels in white adipose tissue of high-fat diet-fed mice, resulting in increased energy expenditure and protection against diet-induced obesity. In contrast, increased liver NNMT expression in humans and mice correlated with an improved metabolic profile, through MNAM-mediated SIRT1 protein stabilization. In cancer cells, overexpression of NNMT resulted in excess consumption of methyl units from SAM, leading to histone hypomethylation that substantially altered the epigenetic landscape. These and other research studies have suggested that NNMT expression may have utility as a diagnostic and prognostic biomarker in cancer. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
